Abstract: OBJECTIVE To observe the effect of benazepril combined with irbesartan in the treatment of chronic heart failure with proteinuria. METHODS All of 116 cases of chronic heart failure with proteinuria were randomly divided into benazepril group(n=38), irbesartan group(n=38) and combined treatment group(n=40). On the basis of comprehensive treatment of heart failure, patients were treated respectively with benazepril, irbesartan or both of them. The changes of the clinical efficacy and clinical indicators were observed after 10 to 12 weeks later. RESULTS The clinical efficacy of combination therapy group was significantly superior than the benazepril group and irbesartan group(P<0.05). The UP, BUN, Cr, NT-proBNP, LVDd, systolic blood pressure and diastolic blood pressure of each group were significantly decreased after treatment(P<0.05 or P<0.01), while LVEF increased(P<0.01). After treatment, the changes of UP, BUN, Cr, NT-proBNP, LVDd, LVEF were more obvious in combined treatment group than those in other two groups(P<0.05 or P<0.01), while the changes of systolic blood pressure and diastolic blood pressure were not obvious(P>0.05). The serum potassium in each group had no significant change before and after treatment(P>0.05). CONCLUSION Combination of benazepril and irbesartan on the basis of comprehensive treatment of heart failure could significantly reduce proteinuria of patients with chronic heart failure and improve heart and kidney functions.